Since
the mid-1990s, pharma companies have devised their
sales and marketing strategies based on Rx data.
However, with the introduction of the AMA’s Prescribing
Data Restriction Program (PDRP) opt-out program
in July 2006, pharma companies need to evaluate
the impact of PDRP violation, mediate their PDRP
compliance strategies, and revisit their existing
Sales Force Effectiveness (SFE) practices. With
the introduction of the PDRP, the use of physician
Rx data by pharmaceutical companies will never be
the same again.
The
PDRP prohibits access to physician-level Rx data,
which directly impacts First Line Managers, Sales
Representatives, and anyone else that accesses or
distributes physician Rx data.
Arrowhead
Publishers' report The Prescribing Data Restriction
Program: Critical Assessment and Best Practices
estimates the impact of PDRP violations, analyzes
the use of Rx data, gauges awareness in the marketplace
and benchmarks the best practices towards PDRP compliance.
Key
features of this report:
-
Best
practices towards PDRP compliance
-
Outline
of the practical implications of the PDRP
-
Industry
perceptions of the PDRP (survey research)
Reasons
to purchase this report:
-
Understand
what other pharma companies are doing to comply
with the PDRP.
-
Learn the financial rewards associated with successful
PDRP compliance strategies
-
Gain
a better understanding of the program and its
implications for the pharma industry
-
Understand
the areas of impact of PDRP violations, and inefficient
PDRP compliance strategies
|
